Autologous bone marrow transplantation in late first complete remission improves outcome in acute myelogenous leukemia
| Autor: | M C, Miggiano, F, Gherlinzoni, G, Rosti, G, Bandini, G, Visani, M, Fiacchini, P, Ricci, N, Testoni, M R, Motta, A, Geromin, S, Rizzi, A, Belardinelli, S, Mangianti, S, Manfroi, S, Tura |
|---|---|
| Rok vydání: | 1996 |
| Předmět: |
Adult
Male Time Factors Adolescent Daunorubicin Remission Induction Cytarabine Middle Aged Prognosis Combined Modality Therapy Transplantation Autologous Disease-Free Survival Survival Rate Leukemia Myeloid Acute Logistic Models Antineoplastic Combined Chemotherapy Protocols Humans Female Idarubicin Busulfan Cyclophosphamide Bone Marrow Transplantation Etoposide Follow-Up Studies Proportional Hazards Models |
| Zdroj: | Leukemia. 10(3) |
| ISSN: | 0887-6924 |
| Popis: | We evaluated the role of ABMT in late 1st CR AML adult patients using busulfan plus cyclophosphamide as preparative regimen. Fifty-one adult patients (mean age 36 years, range 15-59) with AML underwent ABMT in 1st CR. Three of them had a prior diagnosis of myelodysplastic syndrome; one patient had a secondary leukemia. The median interval between CR and ABMT was 8 months (range 4-20). Patients received busulfan, 4 mg/kg/day for 4 days plus cyclophosphamide 50 mg/kg/day for 4 days or 60 mg/kg/day for 2 days. No maintenance chemotherapy was administered after ABMT. Median days to reach 0.5 x 10(9)/I PMN and 20 x 10(9)/I platelets were 26 (range 12-250) and 74 (range 16-740), respectively. No transplant-related deaths were observed. Five-year actuarial overall survival rate is 76.9%; actuarial leukemia-free survival rate is 70.6%. Mean follow-up from ABMT is 35 months. Leukemia-free survival of this group was compared with that of 38 non-transplanted patients younger than 60 years, who maintained a CR longer than 8 months in the same period. This analysis shows a statistically significant difference in favor of ABMT patients. These results suggest that, even if performed late after 1st CR as post-remission intensification, ABMT can improve the outcome of AML patients. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|